A group that championed ivermectin as a COVID-19 cure is now promoting the antiparasitic drug as a treatment for hantavirus, despite no scientific evidence supporting its use against the rare but deadly infection.
The same figures and networks that pushed ivermectin during the pandemic, when health authorities repeatedly warned against it, have resurfaced online making claims about hantavirus treatment. These advocates bypass established medical channels and peer review to spread their recommendations directly to the public.
Ivermectin became a flashpoint during COVID-19. The FDA, CDC, and WHO all cautioned against its use for coronavirus, noting that studies did not support its effectiveness and that it carried risks. Yet the drug gained a devoted following among vaccine skeptics and alternative medicine proponents, who continued promoting it despite regulatory guidance and the lack of rigorous clinical data.
Now, following reports of a hantavirus outbreak, the same advocates are recycling their playbook. They claim ivermectin treats hantavirus without citations to clinical trials or peer-reviewed research. Hantavirus causes severe respiratory distress and carries a mortality rate around 38 percent. No approved drug treats it specifically.
The pattern reflects a broader challenge for public health: once misinformation gains traction around one disease, the same voices and tactics resurface for the next health threat. These networks exploit uncertainty and fear to build audiences skeptical of mainstream medicine.
Public health officials face pressure to communicate clearly about unproven remedies. The CDC and other agencies have spent resources countering COVID-19 misinformation. Hantavirus is rarer, drawing less media attention, which means false claims may spread more easily without immediate fact-checking.
The reappearance of ivermectin advocates signals that pandemic-era medical distrust has not faded. The same communities that rejected official guidance on COVID treatment now position themselves as